Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate 是一种无环单磷酸核苷酸类似物和具有抗病毒活性的 CMV 抑制剂。
| Cas No. | 149394-66-1 |
| 别名 | 西多福韦二水合物; GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate |
| 化学名 | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate |
| Canonical SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O |
| 分子式 | C8H18N3O8P |
| 分子量 | 315.22 |
| 溶解度 | ≥ 34.6mg/mL in Water with gentle warming |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol , and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. References:
[1]. Becker MN, et al. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J. 2008 May 14;5:58.
[2]. Kazory A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007 Jul;60(1):193-4. Epub 2007 May 11.
[3]. Segarra-Newnham M, et al. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001 Jun;35(6):741-4. |
